HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells

References

• Ueno Y, Sakurai H, Tsunoda S, Choo MK, Matsuo M, Koizumi K, Saiki I. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 2008; 123:340-7; PMID:18398842; http://dx.doi.org/10.1002/ijc.23465
   PubMed Web of Science ®Google Scholar
• Allen SD, Garrett JT, Rawale SV, Jones AL, Phillips G, Forni G, Morris JC, Oshima RG, Kaumaya PT. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007; 179:472-82; PMID:17579068; http://dx.doi.org/10.4049/jimmunol.179.1.472
   PubMed Web of Science ®Google Scholar
• Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP. The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol 2010; 74:73-8; PMID:19481955; http://dx.doi.org/10.1016/j.critrevonc.2009.04.011
   PubMed Web of Science ®Google Scholar
• Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012; 12:553-63; PMID:22785351; http://dx.doi.org/10.1038/nrc3309
   PubMed Web of Science ®Google Scholar
• Roskoski R, Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014; 79:34-74; PMID:24269963; http://dx.doi.org/10.1016/j.phrs.2013.11.002
   PubMed Web of Science ®Google Scholar
• Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16:15-31; PMID:22239438; http://dx.doi.org/10.1517/14728222.2011.648617
   PubMed Web of Science ®Google Scholar
• Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Menard S, Croce CM, Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69:2195-200; PMID:19276373; http://dx.doi.org/10.1158/0008-5472.CAN-08-2920
   PubMed Web of Science ®Google Scholar
• Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002; 297:1330-3; PMID:12154198; http://dx.doi.org/10.1126/science.1074611
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55:433-57; PMID:14746530; http://dx.doi.org/10.1146/annurev.med.55.091902.104433
   PubMed Web of Science ®Google Scholar
• Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003; 284:2-13; PMID:12648462; http://dx.doi.org/10.1016/S0014-4827(02)00105-2
   PubMed Web of Science ®Google Scholar
• Sierke SL, Cheng K, Kim HH, Koland JG. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J 1997; 322 (Pt 3):757-63; PMID:9148746; http://www.biochemj.org/bj/322/0757/3220757.pdf
   PubMed Web of Science ®Google Scholar
• Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL, 3rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 1994; 91:8132-6; PMID:8058768; http://dx.doi.org/10.1073/pnas.91.17.8132
   PubMed Web of Science ®Google Scholar
• Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A 2009; 106:21608-13; PMID:20007378; http://dx.doi.org/10.1073/pnas.0912101106
   PubMed Web of Science ®Google Scholar
• Naidu R, Yadav M, Nair S, Kutty MK. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998; 78:1385-90; PMID:9823984; http://dx.doi.org/10.1038/bjc.1998.689
   PubMed Web of Science ®Google Scholar
• Friess H, Yamanaka Y, Kobrin MS, Do DA, Buchler MW, Korc M. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995; 1:1413-20; PMID:9815939; http://clincancerres.aacrjournals.org/content/1/11/1413.full.pdf
   PubMed Web of Science ®Google Scholar
• Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, Korc M, Buchler MW. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998; 29:771-7; PMID:9712416; http://dx.doi.org/10.1016/S0046-8177(98)90444-0
   PubMed Web of Science ®Google Scholar
• Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68:5878-87; PMID:18632642; http://dx.doi.org/10.1158/0008-5472.CAN-08-0380
   PubMed Web of Science ®Google Scholar
• Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10:1813-21; PMID:7538656; http://www.ncbi.nlm.nih.gov/pubmed/7538656
   PubMed Web of Science ®Google Scholar
• Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7:1957-62; PMID:11448910
   PubMed Web of Science ®Google Scholar
• Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007; 7:389-97; PMID:17446858; http://dx.doi.org/10.1038/nrc2127
   PubMed Web of Science ®Google Scholar
• Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends in molecular medicine 2007; 13:527-34; PMID:17981505; http://dx.doi.org/10.1016/j.molmed.2007.10.002
   PubMedGoogle Scholar
• Nahta R, Shabaya S, Ozbay T, Rowe DL. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med 2009; 7:263-74; PMID:20300449; http://dx.doi.org/10.2174/187569209790112337
   PubMedGoogle Scholar
• Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol 2012; 2:62; PMID:22720269; http://dx.doi.org/10.3389/fonc.2012.00062
   PubMedGoogle Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43; PMID:17463250; http://dx.doi.org/10.1126/science.1141478
   PubMed Web of Science ®Google Scholar
• Amler LC. HER3 mRNA as a predictive biomarker in anticancer therapy. Expert Opin Biol Ther 2010; 10:1343-55; PMID:20695834; http://dx.doi.org/10.1517/14712598.2010.512003
   PubMed Web of Science ®Google Scholar
• Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Int J Oncol 2007; 30:509-20; PMID:17203234; http://dx.doi.org/10.3892/ijo.30.2.509
   PubMedGoogle Scholar
• Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, 2nd, de Cremoux P, Stenvang J, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009; 114:263-75; PMID:18409071; http://dx.doi.org/10.1007/s10549-008-0011-8
   PubMed Web of Science ®Google Scholar
• Miller TW, Perez-Torres M, Narasanna A, Guix M, Stal O, Perez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009; 69:4192-201; PMID:19435893; http://dx.doi.org/10.1158/0008-5472.CAN-09-0042
   PubMed Web of Science ®Google Scholar
• Hamburger AW. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J Mammary Gland Biol Neoplasia 2008; 13:225-33; PMID:18425425; http://dx.doi.org/10.1007/s10911-008-9077-5
   PubMedGoogle Scholar
• Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009; 2:ra31; PMID:19567914; http://dx.doi.org/10.1126/scisignal.2000352
   PubMed Web of Science ®Google Scholar
• Li C, Brand TM, Iida M, Huang S, Armstrong EA, van der Kogel A, Wheeler DL. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov Med 2013; 16:79-92; PMID:23998444; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901945/pdf/nihms544643.pdf
   PubMed Web of Science ®Google Scholar
• LoRusso P, Janne PA, Oliveira M, Rizvi N, Malburg L, Keedy V, Yee L, Copigneaux C, Hettmann T, Wu CY, et al. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2013; 19:3078-87; PMID:23591447; http://dx.doi.org/10.1158/1078-0432.CCR-12-3051
   PubMed Web of Science ®Google Scholar
• Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70:2485-94; PMID:20215504; http://dx.doi.org/10.1158/0008-5472.CAN-09-3145
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62; PMID:15637262; http://dx.doi.org/10.1126/science.1104819
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65:11118-28; PMID:16322262; http://dx.doi.org/10.1158/0008-5472.CAN-04-3841
   PubMed Web of Science ®Google Scholar
• Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 2010; 70:1204-14; PMID:20103628; http://dx.doi.org/10.1158/0008-5472.CAN-09-3321
   PubMed Web of Science ®Google Scholar
• Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 2010; 16:1973-8; PMID:20215532; http://dx.doi.org/10.1158/1078-0432.CCR-09-3182
   PubMed Web of Science ®Google Scholar
• Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 2011; 108:5021-6; PMID:21385943; http://dx.doi.org/10.1073/pnas.1016140108
   PubMed Web of Science ®Google Scholar
• Kamath AV, Lu D, Gupta P, Jin D, Xiang H, Wong A, Leddy C, Crocker L, Schaefer G, Sliwkowski MX, et al. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2011; 69(4):1063-9; PMID:22203367; http://dx.doi.org/10.1007/s00280-011-1806-6
   PubMedGoogle Scholar
• Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
   PubMed Web of Science ®Google Scholar
• McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11-0820
   PubMed Web of Science ®Google Scholar
• Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 2013; 73:6024-35; PMID:23928993; http://dx.doi.org/10.1158/0008-5472.CAN-13-1198
   PubMed Web of Science ®Google Scholar
• Mirschberger C, Schiller CB, Schraml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, et al. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res 2013; 73:5183-94; PMID:23780344; http://dx.doi.org/10.1158/0008-5472.CAN-13-0099
   PubMed Web of Science ®Google Scholar
• Lairmore MD, Lal RB, Kaumaya PT. Evaluation of immunodominant epitopes of human T-lymphotropic virus type 1 (HTLV-I) using synthetic peptides. Biomed Peptides Proteins Nucleic Acids: Struct, Syn Biol Act 1995; 1:117-22.
   PubMedGoogle Scholar
• Kaumaya PT, Kobs-Conrad S, Seo YH, Lee H, VanBuskirk AM, Feng N, Sheridan JF, Stevens V. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. J Mol Recognit 1993; 6:81-94; PMID:7508238; http://dx.doi.org/10.1002/jmr.300060206
   PubMedGoogle Scholar
• Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol 2008; 13:485-98; http://dx.doi.org/10.1007/s10911-008-9107-3
   PubMed Web of Science ®Google Scholar
• Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J 2012; 447:417-25; PMID:22853430; http://dx.doi.org/10.1042/BJ20120724
   PubMed Web of Science ®Google Scholar
• Zhang Y, Opresko L, Shankaran H, Chrisler WB, Wiley HS, Resat H. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. BMC Cell Biol 2009; 10:78; PMID:19878579; http://dx.doi.org/10.1186/1471-2121-10-78
   PubMed Web of Science ®Google Scholar
• Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 2005; 23:391-409; PMID:16133791; http://dx.doi.org/10.1007/s10637-005-2899-8
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27:3944-56; PMID:18297114; http://dx.doi.org/10.1038/onc.2008.19
   PubMed Web of Science ®Google Scholar
• Vlacich G, Coffey RJ. Resistance to EGFR-targeted therapy: a family affair. Cancer Cell 2011; 20:423-5; PMID:22014569; http://dx.doi.org/10.1016/j.ccr.2011.10.006
   PubMed Web of Science ®Google Scholar
• Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445:437-41; PMID:17206155; http://dx.doi.org/10.1038/nature05474
   PubMed Web of Science ®Google Scholar
• Jiang N, Saba NF, Chen ZG. Advances in targeting HER3 as an anticancer therapy. Chemother Res Pract 2012; 2012:817304; PMID:23198146; http://dx.doi.org/10.1155/2012/817304
   PubMedGoogle Scholar
• Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8:215; PMID:17096862; http://dx.doi.org/10.1186/bcr1612
   PubMed Web of Science ®Google Scholar
• Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3:269-80; PMID:16683005; http://dx.doi.org/10.1038/ncponc0509
   PubMedGoogle Scholar
• Saladin PM, Zhang BD, Reichert JM. Current trends in the clinical development of peptide therapeutics. IDrugs 2009; 12:779-84; PMID:19943221; http://www.ncbi.nlm.nih.gov/pubmed/19943221
   PubMed Web of Science ®Google Scholar
• Reichert J. Development trends for peptide therapeutics. Tufts Center for the Study of Drug Development Tufts University, 2008. Peptide Therapeutics Foundation, San Diego CA 92121; http://www.peptidetherapeutics.org/PTF_report_summary_2010.pdf
   Google Scholar
• Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem 2011; 286:13626-37; PMID:21325276; http://dx.doi.org/10.1074/jbc.M110.216820
   PubMed Web of Science ®Google Scholar
• Foy KC, Miller MJ, Moldovan N, Carson Iii WE, Kaumaya PT. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology 2012; 1:1048-60; PMID:23170253; http://dx.doi.org/10.4161/onci.20708
   PubMed Web of Science ®Google Scholar
• Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv 2013; 4:1443-67; PMID:24228993; http://dx.doi.org/10.4155/tde.13.104
   PubMedGoogle Scholar
• Miller MJ, Foy KC, Kaumaya PT. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med 2013; 15:166-76; PMID:23545045; http://www.discoverymedicine.com/Megan-Jo-Miller/2013/03/28/cancer-immunotherapy-present-status-future-perspective-and-a-new-paradigm-of-peptide-immunotherapeutics/
   PubMed Web of Science ®Google Scholar
• Srinivasan M, Gienapp IE, Stuckman SS, Rogers CJ, Jewell SD, Kaumaya PT, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J Immunol 2002; 169:2180-8; PMID:12165548; http://dx.doi.org/10.4049/jimmunol.169.4.2180
   PubMedGoogle Scholar
• Srinivasan M, Wardrop RM, Gienapp IE, Stuckman SS, Whitacre CC, Kaumaya PT. A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro. J Immunol 2001; 167:578-85; PMID:11418697; http://dx.doi.org/10.4049/jimmunol.167.1.578
   PubMedGoogle Scholar
• Allen SD, Rawale SV, Whitacre CC, Kaumaya PT. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. J Pept Res 2005; 65:591-604; PMID:15885118; http://dx.doi.org/10.1111/j.1399-3011.2005.00256.x
   PubMedGoogle Scholar
• Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000; 60:3782-9; PMID:10919651; http://cancerres.aacrjournals.org/content/60/14/3782.full.pdf+html
   PubMed Web of Science ®Google Scholar
• Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 2003; 170:4242-53; PMID:12682258; http://dx.doi.org/10.4049/jimmunol.170.8.4242
   PubMed Web of Science ®Google Scholar
• Dakappagari NK, Sundaram R, Rawale S, Liner A, Galloway DR, Kaumaya PT. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice. J Pept Res 2005; 65:189-99; PMID:15705163; http://dx.doi.org/10.1111/j.1399-3011.2005.00212.x
   PubMedGoogle Scholar
• Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, Reilly RT, Kaumaya PT. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem 2005; 280:54-63; PMID:15507452; http://dx.doi.org/10.1074/jbc.M411020200
   PubMed Web of Science ®Google Scholar
• Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol 2009; 27:5270-7; PMID:19752336; http://dx.doi.org/10.1200/JCO.2009.22.3883
   PubMed Web of Science ®Google Scholar
• Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004; 108:334-41; PMID:14648698; http://dx.doi.org/10.1002/ijc.11445
   PubMed Web of Science ®Google Scholar
• Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, Sagar M, Wong TW, Gottardis MM, Erlichman C. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008; 7:2589-98; PMID:18765823; http://dx.doi.org/10.1158/1535-7163.MCT-08-0493
   PubMed Web of Science ®Google Scholar
• Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99:1415-25; PMID:18841159; http://dx.doi.org/10.1038/sj.bjc.6604700
   PubMed Web of Science ®Google Scholar
• Larbouret C, Gaborit N, Chardes T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pelegrin A. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' downregulation and dimers' disruption. Neoplasia 2012; 14:121-30; PMID:22431920
   PubMed Web of Science ®Google Scholar
• Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013; 73:824-33; PMID:23172311; http://dx.doi.org/10.1158/0008-5472.CAN-12-1611
   PubMed Web of Science ®Google Scholar
• Ioannou N, Seddon AM, Dalgleish A, Mackintosh D, Modjtahedi H. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer 2013; 13:41; PMID:23367880; http://dx.doi.org/10.1186/1471-2407-13-41
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3:273-88; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E, et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011; 286:4703-17; PMID:21123183; http://dx.doi.org/10.1074/jbc.M110.184317
   PubMed Web of Science ®Google Scholar
• Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther 2014; 13:410-25; PMID:24282274; http://dx.doi.org/10.1158/1535-7163.MCT-13-0255
   PubMed Web of Science ®Google Scholar
• Chen C, Zhang Y, Li J, Tsao SW, Zhang MY. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor. Mol Cancer Ther 2014; 13:90-100; PMID:24227890; http://dx.doi.org/10.1158/1535-7163.MCT-13-0558
   PubMedGoogle Scholar
• Garrett JT, Rawale S, Allen SD, Phillips G, Forni G, Morris JC, Kaumaya PT. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol 2007; 178:7120-31; PMID:17513761; http://dx.doi.org/10.4049/jimmunol.178.11.7120
   PubMedGoogle Scholar
• Foy KC, Wygle RM, Miller MJ, Overholser JP, Bekaii-Saab T, Kaumaya PT. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol; 191:217-27; PMID:23698748; http://dx.doi.org/10.4049/jimmunol.1300231
   PubMedGoogle Scholar